A Menopause Society meeting study of 3,855 women found a lasting edge only with semaglutide. Experts caution it's an association, not a reason to start hormones.
Recap by typeshit. Full story at Healthline.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
Johns Hopkins researchers found its early uptake curve was 4.4 times steeper than Zepbound's, and injectable Wegovy prescriptions didn't fall after the pill arrived.
EMY says the FDA has added a new warning covering weight loss drugs such as Wegovy. The listing gives no detail on what the warning says, so tap through.
Loading…